Aprea, a Karolinska Development portfolio company, has reported positive clinical data of its investigational drug, APR-246, from a Phase I/II study.

The study enrolled 22 patients to demonstrate the safety and efficacy of APR-246 in treating patients with advanced blood or prostate cancer, according to the company.

Escalating doses of APR-246 were administered as monotherapy to 22 patients on up to four consecutive days during the study, which demonstrated dose-proportional and time-independent pharmacokinetics for APR-246 over the dose range studied.

The results further noted that the drug has good tolerability, and shows 50% reduction in the number of blast cells in the bone marrow, as well as dose limiting toxicity at plasma levels.

In addition to the tolerability, the study also concluded that APR-246 induces biological effects and that there are cases of clinical effects on tumor burden.

Karolinska Development CEO Torbjörn Bjerke said the data indicates that APR-246 has an anti-tumor effect.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"APR-246 was well tolerated and, importantly, the safety profile is different from traditional cytostatic drugs," Bjerke said.

"With these new results we can see a clear path forward for APR-246, especially in carboplatin-resistant patients."

Aprea CEO Ulf Björklund said; "We are now planning to take the p53-activating compound APR-246 forward into a Phase II-trial in epithelial ovarian cancer with mutated p53 in combination with conventional chemotherapy."